ArticleGastro hep advances2026
Artificial Intelligence for Anal Cancer Screening: Multicenter Multicontinental Validation of a Trinary Model in High-Resolution Anoscopy.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Anal cancer incidence is rising, primarily due to increasing rates of human papillomavirus infection. High-resolution anoscopy (HRA) is the gold standard diagnostic modality for evaluating human papillomavirus-related anal lesions; however, its broader adoption is limited by subjectivity and interobserver variability. This study aims to develop and validate a deep learning-based trinary classification model that detects and classifies high-grade squamous intraepithelial lesion (HSIL), low-grade squamous intraepithelial lesion (LSIL), and non-dysplastic lesions (eg, inflammation) on HRA frames. Methods: A multicentric study was conducted to develop a convolutional neural network for automatic detection and classification of HSIL, LSIL, and non-dysplastic lesions. A You Only Look Once (YOLO)-v11 model was trained and validated on 191,951 frames (from 107 HRA procedures) containing histologically confirmed lesions, collected from 5 different imaging devices across 5 independent centers. Performance metrics (recall, precision, accuracy, and F1-score) were calculated at the object classification level as weighted averages across 5 confidence thresholds (0.45, 0.47, 0.50, 0.52, and 0.55). Results: For HSIL and LSIL, recall was 97.9% and 98.9%, and precision was 93.9% and 98.5%, respectively. For non-dysplastic lesions, recall was 98.7%, and precision was 96.0%. The overall classification accuracy on the test set was 88.1% (95% CI: 78.2-98.1). Conclusion: This is the first interoperable artificial intelligence model capable of simultaneous detection and trinary classification of anal canal lesions (HSIL, LSIL, and non-dysplastic mimickers). By addressing key limitations of HRA, this model supports broader clinical applicability and represents a significant step toward real-world deployment and personalized artificial intelligence-assisted care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.